LGALS9 and hepatocellular carcinoma: Among malignant tissues, galectin-9 expression on the cell surface has been reported to be reduced in hepatocellular carcinoma (HCC) as well as in other solid tumors, such as prostate cancer [75], cervical cancer [76], and skin cancer [77,78].